 |
|
|
|
|
|
|
|
 |
|
||||||
 |
 |
 |
 |
 |
 |
 |
|
Analyst Conference Summaries
Juno Therapeutics
JUNO
conference date: November 1, 2017 @ 2:00 PM Pacific Time
Since Juno has been bought by Celgene, there will be no further coverage.
See Celgene to Acquire Juno Therapeutics
Juno Therapeutics: Celgene Partnership and CAR-T Pipeline Value [Sept. 9, 2015]
June Therapeutics Reports Q2 2015 Results [August 12, 2015]
2017 |
|||
May 4, 2017 |
August 3, 3017 |
Nov. 1, 2017 |
|
2016 |
|||
05/09/2016 |
08/04/2016 |
11/09/2016 |
03/01/2017 |
2015 |
|||
JUNO Q2 not available |
|||
08/12/2015 |
11/10/2015 |
02/29/2016 |
|
Juno Therapeutics (JUNO) is a clinical development stage biotechnology company specializing in immunotherapy.
More Analyst Conference Pages:
| AGEN |
| AGIO |
| ALNY |
| ALXN |
| AMAT |
| AMD |
| AMGN |
| BIIB |
| CLDX |
| CELG |
| EPZM |
| GILD |
| GLYC |
| INO |
| INTC |
| ISRG |
| JUNO |
| MACK |
| MCHP |
| MYL. |
| NVDA |
| PLX |
| REGN |
| SGEN |
| XLNX |
| XLRN |
Disclaimer: Our analyst summaries may include both our condensations of statements made by company representatives and our own analysis. They are not covered by any warranty. We cannot guarantee anything said by company representatives is true. We try not to make errors, but it is possible. This is investment journalism, not financial advice.
Copyright 2015 William P. Meyers